期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

治疗性乙型肝炎病毒载体疫苗的构建 被引量：2

Construction of Recombinant Virus As A Therapeutic Hepatitis B Vaccine
下载PDF
导出
摘要 目的研制治疗慢性乙型肝炎的重组修饰的Ankara痘病毒(MVA)载体疫苗。方法将HBV的表面抗原基因克隆到MVA病毒的重组载体pSC11上,重组质粒与空MVA病毒共转染鸡胚成纤维细胞(CEF),进行同源重组。经过10轮筛选,挑选出阳性的重组MVA病毒。经PCR鉴定,感染不同细胞系,确定病毒表达量。结果获得目的重组MVA病毒,ELISA检测到表面抗原在不同细胞系中的表达。结论已成功地构建了表达HBV表面抗原的重组MVA病毒。 Objective To prepare the recombinant modified vaccinia Ankara（MVA） virus expressing HBsAg as a therapeutic vaccine for chronic hepatitis B. Methods Clone HBsAg gene to the shuttle vector pSC11, and co-transfect chick embryo fibroblast （CEF） with the constructed recombinant plasmid and empty MVA virus for homologous recombination. The positive clones were screened,identified by PCR and used for the infection of three different cell lines to determine the expression of HBsAg. Results The HBsAg gene fragment at a length of 681 bp was amplified from the constructed recombinant MVA virus. ELISA proved the expression of HBsAg in all the three cell lines. Conclusion The recombinant MVA virus for expression of HBsAg was successfully constructed.
作者 陈宇 杨小松 李惟 孔维
机构地区 吉林大学生命科学学院疫苗研究中心
出处 《中国生物制品学杂志》 CAS CSCD 2006年第5期474-476,共3页 Chinese Journal of Biologicals
关键词 乙型肝炎 修饰的Ankara痘病毒 治疗性疫苗 Hepatitis B Modified vaccinia Ankara（MVA） Therapeutic vaccine
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献11

  • 1Lee WM.Hepatitis B virus infection.New Engl J Med,1997,337(24):1733 -1745.
  • 2Niederau C,Heintges T,Lange S,et al.Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.N Engl J Med,1996,334(22):1422-1427.
  • 3Dienstag JL,Schiff ER,Wright TL,et al.Lamivudine as initial treat-ment for chronic hepatitis B in the United States.New Engl J Med,1999,341 (17):1256-1263.
  • 4Chizari FV.Viruses,immunity,and cancer:lessons from hepatitis B.Am J Pathol,2000,156(4):1117-1132.
  • 5Ramirez JC,Gherardi MM,Esteban M.Biology of attenuated modified vaccine virus Ankara recombinant vector in mice:virus fate and activation with the B-and T-cell immune responses in comparsion with the Western reserve strain and advantages as a vaccine.J Virol,2000,74(2):923-933.
  • 6Stickl H,Hcchstein-Mintzel V.Intracutaneous smallpox vaccination with a weak pathogenic vaccinia virus("MVA virus").Munch Med Wcchenschr,1971,113(35):1149-1153.
  • 7Stickl H,Hcchstein-Mintzel V,Mayr A,et al.MVA vaccination against smallpox:clinical tests with an attenuated live vaccinia virus strain (MVA).Dtsch Med Wochenschr,1974,99 (47):2386 -2392.
  • 8Sutter G,Wyatt LS,Foley PL,et al.A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus.Vaccine,1994,12(11):1032-1040.
  • 9Wyatt LS,Shors ST,Murphy BR,et al.Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model.Vaccine,1996,14(15):1451-1458.
  • 10Stittelaar KJ,Wyatt LS,De Swart RL,et al.Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies.J Virol,2000,74(9):4236-4243.

同被引文献14

  • 1梁晓峰,陈园生,王晓军,贺雄,陈丽娟,王骏,林长缨,白呼群,严俊,崔钢,于竞进.中国3岁以上人群乙型肝炎血清流行病学研究[J].中华流行病学杂志,2005,26(9):655-658. 被引量：967
  • 2Beckebaum S, Cicinnati VR, Gerken G. DNA-based immunotherapy: 89 potential for treatment of chronic viral hepatitis[J ]? Med Virol, 2002, 12: 297-319.
  • 3Greiner S. Humrich JY. Thuman P, et al. Tile highly altenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity[J]. Clin Exp Immunol, 2006, 146(2): 344-53.
  • 4Ramsburg E, Rose NF, Preston A, et al. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol[J]. J Virol, 2004, 78(8): 3930-40.
  • 5Moorthy VS, Pinder M, Reece WH, et al. Safety and immunogenicity of DNA/modified vaccinia virus Ankara malaria vaccination in African adults[J].J Infect Dis, 2003. 188(8): 1239-44.
  • 6Moroziewicz D, Kaufman HL. Gene therapy with poxvirus vectors [J].Curr Opin Mol Ther, 2005, 7(4): 317-25.
  • 7Hatter EM, Bauerle B, Ferst L, et al, Therapeutic vaccination of HIV-1-infeeted patients on HAART with a recombinant HIV-1 nel: expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption[ J ]. Antivir Ther, 2005, 10(2): 285-300.
  • 8Hebben M. Brants J. Birck C. et al. High level protein expression in mammalian cells using a safe viral vector: Modified vaccinia virus Ankara[J]. Protein Expr Purif, 2007.56(2): 269-78.
  • 9Kuhober A, Wild J, Pudollek HP, et al. DNA vaccine with plasmids encoding the intracellular (HBcAg) or secreted (HBeAg) form of the core protein of hepatitis B virus primes T cell response to two overlapping Kb-and Kd-restricted epitopes[J].Int Immunol, 1997, 9(8): 1203-12.
  • 10Beckebaum S,Cicinnati VR, Gerken G. DNA-based immunotherapy: potential for treatment of chronic viral hepatitis?[J]. Rev Med Virol, 2002,12(5):297-319.

引证文献2

二级引证文献2

中国生物制品学杂志
2006年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部